The narrative of the BRCA1 and BRCA2 genetic mutations has long been framed as a women’s health issue. For decades, public health campaigns, pink ribbons, and clinical outreach have focused almost exclusively on the risks of breast and ovarian cancers. However, the story of Doug Bank, a lifelong cancer advocate and survivor, serves as a poignant reminder that genetic risk does not respect gender boundaries.
The reality is that men are not only carriers of these mutations—capable of passing them on to their children with a 50% probability—but are also at significantly elevated risk for a spectrum of lethal malignancies, including prostate, pancreatic, and male breast cancer. As the medical community moves toward a more holistic view of hereditary cancer, Bank’s journey underscores a critical imperative: men must be integrated into the conversation about genetic testing and family health history.
Main Facts: A Generational Battle with BRCA2
The crux of the issue lies in the misconception that BRCA (an abbreviation for BReast CAncer gene) only affects female anatomy. In reality, everyone has BRCA1 and BRCA2 genes; their purpose is to repair cell damage and prevent tumor growth. When these genes are mutated, they lose their protective function.
For Doug Bank, the realization of his carrier status was not a sudden epiphany but a slow, calculated uncovering of a family legacy. Carrying a BRCA2 mutation, Bank has navigated three decades of cancer-related challenges:
- A Personal History: Bank survived Stage I testicular cancer at age 26 and later developed BRCA2-related prostate cancer at age 56.
- The Family Toll: The mutation claimed the life of his brother via pancreatic cancer and led to a breast cancer diagnosis for his daughter at the remarkably young age of 24.
- The Gender Blind Spot: Despite his extensive background in cancer advocacy, Bank initially resisted genetic testing, illustrating the pervasive "it’s a women’s issue" stigma that prevents many men from seeking life-saving information.
- The Role of Sharsheret: The national non-profit organization Sharsheret, which initially focused on Jewish women and families facing breast and ovarian cancer, has become a vital resource for men like Bank, helping them navigate the complexities of hereditary risk.
Chronology: From a Single Diagnosis to a Family Map
Doug Bank’s intersection with the oncology world began in the mid-1990s. At age 26, he was diagnosed with Stage I testicular cancer. While testicular cancer is not typically associated with BRCA mutations, the experience was foundational. Bank found himself navigating a medical system that often pushed for overly aggressive treatments. His quest for clarity led him to found a website and a nonprofit dedicated to helping other men navigate the fear and confusion of a cancer diagnosis.
By the early 2000s, Bank’s advocacy work expanded. He became a key figure in the LIVESTRONG Young Adult Alliance, where he met Rochelle Shoretz, the founder of Sharsheret. At the time, Sharsheret was a burgeoning organization focused on the unique needs of young Jewish women with breast cancer. Bank, a father of a young daughter, felt a kinship with Shoretz’s mission but did not yet realize how intimately their paths would converge.
The turning point occurred years later during a routine medical visit for his wife. When the physician inquired about Bank’s family history, the "pedigree"—a clinical term for a multi-generational family tree—revealed a startling pattern. Bank’s father had prostate cancer; his aunt and grandmother had suffered from cancer; and a deeper dive revealed that every one of his father’s female cousins had been diagnosed with breast or ovarian cancer.
In 2009, Bank tested positive for the BRCA2 mutation. This knowledge transformed his family’s medical strategy. When his brother was diagnosed with pancreatic cancer, the genetic context allowed for more targeted, albeit ultimately unsuccessful, treatments. Most importantly, the knowledge allowed Bank to advocate for his children. Despite pushback from physicians who worried about the "anxiety" of testing young adults, Bank insisted. Two of his children carried the mutation. Because his daughter knew her status, a lump found at age 24 was treated with immediate, high-risk protocols rather than being dismissed as a benign cyst—a move that likely saved her life.
In a final, personal confirmation of the mutation’s potency, Bank was diagnosed with prostate cancer at age 56, a common manifestation of BRCA2 in men.
Supporting Data: The Statistical Weight of BRCA in Men
The scientific data supports Bank’s insistence that men are central to the BRCA narrative. According to the National Cancer Institute and the Centers for Disease Control and Prevention (CDC), the risks for men with BRCA mutations are substantial:
1. Prostate Cancer
Men with a BRCA2 mutation have a 20% to 25% lifetime risk of developing prostate cancer, compared to about 12% in the general population. More importantly, BRCA-related prostate cancers tend to be more aggressive, occur at a younger age, and are more likely to metastasize.
2. Pancreatic Cancer
While pancreatic cancer is relatively rare, BRCA2 mutations significantly increase the risk. Approximately 5% to 10% of pancreatic cancer patients have a hereditary mutation, with BRCA2 being one of the most common. This link is critical because pancreatic cancer is often difficult to detect in its early, treatable stages.
3. Male Breast Cancer
While often overlooked, men can and do develop breast cancer. A BRCA2 mutation increases a man’s lifetime risk of breast cancer to approximately 7%, a staggering increase from the 0.1% risk found in the general male population.
4. The Ashkenazi Jewish Connection
The prevalence of BRCA mutations is notably higher in certain populations. Among individuals of Ashkenazi Jewish descent, 1 in 40 carries a BRCA mutation, compared to about 1 in 400 in the general population. This "founder effect" makes genetic literacy particularly vital within this community, though the mutations affect individuals of all ethnic backgrounds.
Official Responses and Clinical Perspectives
Medical organizations and advocacy groups are beginning to shift their guidelines to reflect the importance of male testing. The National Comprehensive Cancer Network (NCCN) now includes specific criteria for men to undergo genetic testing, particularly if there is a strong family history of breast, ovarian, prostate, or pancreatic cancer.
Genetic counselors emphasize that a "negative" family history of cancer in a man’s paternal line can be misleading. If a mutation is passed through several generations of men, it may remain "silent" because men do not have ovaries and have significantly less breast tissue, making the cancers less frequent than in their female counterparts.
"Men are often the ‘silent carriers’ who bridge the gap between two generations of women with cancer," says one genetic counselor. "By the time a man is diagnosed with a BRCA-related cancer, his daughters or sisters may have already missed the window for early prevention. We need to catch these mutations in the men before the next generation is at risk."
Sharsheret has responded to this need by establishing a Men’s Leadership Council, of which Doug Bank is a member. The organization has expanded its outreach to include "Sharsheret for Men," providing resources tailored to the psychological and clinical needs of male carriers. Their message is clear: genetic information is not a burden; it is a tool for family preservation.
Implications: Knowledge as a Preventive Shield
The story of the Bank family illustrates the profound implications of genetic literacy. The shift from a reactive medical model—waiting for a lump or a pain to appear—to a proactive model based on genetic risk can be the difference between life and death.
Breaking the Stigma
For many men, the resistance to genetic testing is rooted in a desire to avoid "unnecessary" anxiety. However, as Bank points out, the anxiety of not knowing is often more paralyzing than the clarity of a test result. Knowing a mutation exists allows for increased surveillance, such as more frequent PSA (Prostate-Specific Antigen) tests, MRIs, and specialized screenings that the general population does not receive.
The Multi-Generational Impact
When a man discovers he is a BRCA carrier, he provides his children with the opportunity to take control of their health in their 20s rather than their 50s. In the case of Bank’s daughter, her "high-risk" status ensured she was seen by specialists who took her concerns seriously, bypassing the common medical bias that young women are "too young" for breast cancer.
A Call to Action for Families
The primary takeaway from Bank’s experience is the importance of the "pedigree." Families are encouraged to have honest, often difficult conversations about their medical histories. This includes looking beyond the immediate nuclear family to aunts, uncles, and cousins on both the maternal and paternal sides.
As Doug Bank concludes, men should no longer stand on the sidelines of the BRCA conversation. They are essential participants who can carry the risk, develop the disease, and, most importantly, provide the knowledge necessary to protect their families. In the world of oncology, knowledge is power, and for families carrying a BRCA mutation, that power is the most effective medicine available.
About the Author
